Applied DNA exits DNA tagging business, cuts 20% headcount; Q1 revenue $1.2M (+34% YoY), net loss $2.7M

BNB PLUS CORP.

2025-Q1 EPS reported -$0.56 vs consensus -$45.90 ▲ beat (+98.8%)

Revenue $1.2M (+34% YoY); operating loss $3.0M vs $3.8M; net loss $2.7M vs $1.1M.
Exiting DNA Tagging segment; workforce reduction 20% (13% annual payroll cut); ~$300k severance in Q2 FY25.
GMP Site 1 completed Jan 31, 2025, ISO 7/5 certified; projected annual revenue $10M-$30M at full capacity.
Cash $9.3M as of Dec 31, 2024, includes $5.7M net from October registered direct offering.
First-in-human clinical validation of Linea DNA in CAR-T therapy under Czech regulatory approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.